Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Sage To…
SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline…
SAN DIEGO, Sept. 01, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP…
NEW YORK, Sept. 01, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…
NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law…
NEW YORK, Aug. 03, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
The Global Mother and Child Healthcare Market Size was Valued at USD 723.67 Billion in 2023 and the Worldwide Global…
…
Sage Therapeutics (SAGE) incurs a wider-than-expected second-quarter 2024 loss. Collaboration revenues from Zurzuvae drive year-over-year revenue growth.…
Sage Therapeutics (SAGE) and Agenus (AGEN) are in the spotlight following study failure and regulatory updates, respectively.…
Sage Therapeutics stock sinks after drug study failed…
…
Baird predicts steady growth for SAGE Therapeutics at $15 target…
NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
NEW YORK, May 12, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
Sage Therapeutics (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression…
…
Regeneron (REGN) and Sage Therapeutics (SAGE) are in focus on regulatory and pipeline updates.…
Earnings call: Agile Therapeutics reports growth amid challenges in Q4…
…
…
HUNTSVILLE, Ala., March 26, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (NYSE American: SER), a clinical-stage biotechnology company developing…
Agile Therapeutics to be delisted from Nasdaq…
PRINCETON, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”),…
ALAMEDA, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company…
Agile Therapeutics clears debt with Perceptive Advisors…
Agile Therapeutics reduces warrant exercise price…
PRINCETON, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”),…
Sage Therapeutics (SAGE) earnings and revenues surpass estimates in the fourth quarter of 2023. Focus on newly launched PPD drug,…
…
…
…
…
…
…
…
Sage Therapeutics (SAGE) reports dismal third-quarter results. It intends to price the recently approved oral postpartum depression pill Zurzuvae at…
…
…
…
The FDA grants orphan drug designation to Sage Therapeutics (SAGE) SAGE-718 for treating Huntingtons disease. The designation will help incentivize…
…
PRINCETON, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today…
The pharmaceutical companys growth prospects have taken a big hit....…
Barrett, Elizabeth - Aufsichtsrat - Tag der Transaktion: 2023-08-09...…
The company got bad news from the FDA and saw increased losses....…
A regulatory setback weighed heavily on the drugmakers shares Monday....…
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING…
Sages regulatory win wasnt enough to offset an even bigger regulatory loss....…